FAQ on Quantum BioPharma Ltd.'s $600 Private Placement of Class A Multiple Voting Shares

What is Quantum BioPharma Ltd.’s recent announcement about?

Quantum BioPharma Ltd. announced a non-brokered private placement of Class A Multiple Voting Shares (MVS) at $50 per share for gross proceeds of up to $600, expected to be fully subscribed by existing MVS holders.

Why is this private placement significant?

This private placement is significant as it supports the company’s general working capital needs and involves related-party transactions under MI 61-101, relying on exemptions due to the transaction’s limited size relative to market capitalization.

How does the private placement work?

The private placement involves selling Class A Multiple Voting Shares at $50 per share, with all issued securities carrying a four-month-plus-one-day hold under Canadian securities laws.

Who is involved in this private placement?

Existing MVS holders, including entities linked to CEO Zeeshan Saeed and director Anthony Durkacz, are involved in this private placement.

When does this private placement take effect?

The private placement is announced as of the press release date, with securities issued carrying a four-month-plus-one-day hold period under Canadian securities laws.

Where can I find more information about this private placement?

More information can be found in the full press release at https://ibn.fm/9A9Lc and in the company’s newsroom at https://ibn.fm/QNTM.

What are the implications of this private placement for Quantum BioPharma Ltd.?

The private placement provides Quantum BioPharma Ltd. with necessary working capital, supporting its operations and development of innovative biotech assets.

What should investors know about this private placement?

Investors should be aware that this is a related-party transaction under MI 61-101, with exemptions applied due to its size, and that the securities issued have a hold period under Canadian securities laws.